The decision by Fineco, the Italian asset management firm, to delist from Germany's Neuer Markt has cast further doubt on the benefits of European companies being listed outside their domestic market.

Fineco's move comes in the same week that Innogenetics, the Nasdaq Europe listed Belgian biotech firm, applied to join Euronext Brussels in a bid to increase its investor visibility.